Evidence map›Paper›PMID 29380353›Full record

ArticleClinical pharmacology and therapeutics2018

Regenerative Solutions for Inherited Diseases.

Jakub Tolar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jakub TolarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis BullosaR01AR063070 · NIAMS · UNIVERSITY OF MINNESOTA · PI Mark J Osborn, Jakub Tolar · 2013 to 2026
$4.5M
Testing the Therapeutic Potential of iPS Cells for Inherited Skin DiseasesR01AR059947 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ROOP, DENNIS · 2012 to 2017
$2.1M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NIAMS NIH HHS R01 AR059947NIAMS NIH HHS R01 AR063070
6 · The paper itself

Abstract

It is clear that regenerative medicine therapies will dominate the future landscape, particularly for genetic disorders and other diseases that have been proven intractable with current therapies. As we explore unique combinations of rapidly emerging fields-from computational biology to genome editing to molecular therapeutics-the past goal of ameliorating symptoms of disease is rapidly giving way to the goal of restoring a patient to health and normal function.

Indexed as

Computational BiologyDiseaseGene EditingGenetic Diseases, InbornHumansRegenerative MedicineWills

Identifiers

PMID29380353
PMCPMC9309030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.